Skip to content
All research profiles

GH secretagogue

Tesamorelin

Prepared by the ezGLP team. Sources last checked .

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

Tesamorelin is listed in the ezGLP knowledgebase under GH secretagogue. Evidence and regulatory status can vary by formulation, route, and jurisdiction.

Category
GH secretagogue
Routes represented
Subcutaneous (SubQ)
Approximate library half-life
0.5 hours; formulation-dependent and not dosing guidance
Storage context
Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.

Published literature

Safety evidence

Common or reported: edema, joint or muscle pain, tingling or carpal-tunnel symptoms, headache, injection-site reactions.

Serious or important: intracranial hypertension, glucose intolerance or diabetes, adrenal insufficiency, pancreatitis, malignancy-related warnings.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With glucocorticoid replacement

Safety flag

GH-axis stimulation can reduce cortisone-to-cortisol conversion and unmask or worsen adrenal insufficiency.

Interaction evidence source

With glucose-lowering medicines

Safety flag

GH-axis stimulation can reduce insulin sensitivity and alter glucose control.

Interaction evidence source

With another GH/IGF-axis medicine

Safety flag

Duplicate GH/IGF-axis stimulation may amplify IGF-1 elevation, edema, joint symptoms, and glucose intolerance.

Interaction evidence source

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.